Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PRedSS: Prednisolone in Early Diffuse Cutaneous Systemic Sclerosis
NCT03708718Phase 2Completed
- Start
- Dec 2017
- Primary completion
- Mar 2021
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of prednisolone in systemic sclerosis (SSc). Primary endpoint: Health Assessment Questionnaire Disability Index at 3 months. Started Dec 2017; status: completed.
02
Drugs
prednisolone
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT03708718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708718.